June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending that patients being treated for visual impairment caused by chronic diabetic macular oedema ...

NEW YORK — Infectious endophthalmitis after intravitreal dexamethasone implant is rare but more frequent than after anti-VEGF injections, according to a poster presented at the American Society of ...

Outcomes for patients with diabetic macular edema did not have treatment with intravitreal dexamethasone implants affected by their glycosylated hemoglobin. Patients who have diabetic macular edema ...

Reduced treatment burden for neovascular age-related macular degeneration met with overwhelming approval in an analysis of patient-reported outcomes (PROs) from a randomized trial. After 40 weeks of ...

SEATTLE -- An ocular implant containing a reformulated cancer drug preserved vision and stabilized retinal thickening for up to a year while dramatically reducing treatment burden for neovascular ...

brolucizumab-dbll Beovu 6mg/0.05mL soln for intravitreal inj 6mg (0.05mL) every 6wks (approx. 39–45 days) for the 1st 5 doses, followed by 6mg (0.05mL) once every 8–12wks. ranibizumab Lucentis 6mg/mL ...